Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
BACKGROUND
Objectively measured circulating biomarkers of prognosis complementing existing clinicopathological models are needed in renal cell carcinoma (RCC).


METHODS
Blood samples collected from 216 RCC patients in Leeds before nephrectomy (median follow-up 7 years) were analysed for C-reactive protein (CRP), osteopontin (OPN) and carbonic anhydrase IX (CA9) and prognostic significance determined.


RESULTS
CA9, OPN and CRP were univariately prognostic for overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS) with CRP and CA9 being independently prognostic for OS/CSS and OS, respectively. Including CA9, OPN and CRP with other conventional prognostic factors gave a superior predictive capacity when compared with a previously published pre-operative clinical nomogram (Karakiewicz et al, 2009). Osteopontin outperformed this nomogram and the post-operative SSIGN score for OS but not for CSS, being significantly predictive for non-cancer deaths. Osteopontin, CRP and CA9 outperformed stage (c-index 76% compared with 70% for stage) and OPN or CA9 identified several subsets of poor prognosis patients including in T1 patients, who may benefit from adjuvant therapy and increased surveillance.


CONCLUSIONS
Circulating CA9, OPN and CRP add value to existing clinicopathological prognostic factors/models and support further studies to investigate their potential use in improving the clinical management of RCC.
St James's Institute of Oncology, Bexley Wing, St James's University Hospital, Leeds, UK.
S H
SH
Sim
M P
MP
Messenger
W M
WM
Gregory
T C
TC
Wind
N S
NS
Vasudev
J
J
Cartledge
D
D
Thompson
P J
PJ
Selby
R E
RE
Banks
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D030741:Carbonic Anhydrase IV / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000201:enzymology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000379:methods; D053495:Osteopontin / Q000097:blood*; D011379:Prognosis
D014408:Biomarkers, Tumor; D053495:Osteopontin; D002097:C-Reactive Protein; D030741:Carbonic Anhydrase IV; C548247:CA4 protein, human